Justin Zelin
Stock Analyst at BTIG
(1.66)
# 3,388
Out of 5,056 analysts
43
Total ratings
29.27%
Success rate
-9.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRSN Mersana Therapeutics | Downgrades: Neutral | n/a | $27.54 | - | 1 | Nov 13, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Buy | $50 | $32.00 | +56.25% | 1 | Nov 10, 2025 | |
| TCRX TScan Therapeutics | Downgrades: Neutral | n/a | $0.99 | - | 2 | Nov 4, 2025 | |
| IPHA Innate Pharma | Reiterates: Buy | $8 | $1.80 | +344.44% | 1 | Oct 29, 2025 | |
| SNDX Syndax Pharmaceuticals | Reiterates: Buy | $56 | $17.09 | +227.68% | 4 | Oct 27, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $62 | $33.71 | +83.92% | 3 | Oct 21, 2025 | |
| CAN Canaan | Reiterates: Buy | $8 | $1.03 | +676.70% | 1 | Oct 14, 2025 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $125 | $37.76 | +231.04% | 5 | Sep 22, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $20 → $7 | $1.83 | +282.51% | 3 | Sep 22, 2025 | |
| VSTM Verastem | Reiterates: Buy | $20 | $9.27 | +115.75% | 2 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.10 | +185.71% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $22.59 | +85.92% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.65 | - | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,000 → $800 | $1.23 | +64,940.65% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $38.06 | +139.10% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $0.60 | +1,563.34% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.28 | +601.75% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $29.42 | +205.91% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $11.08 | +179.78% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $47.55 | -67.40% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $10 | $1.21 | +726.45% | 3 | Nov 16, 2022 |
Mersana Therapeutics
Nov 13, 2025
Downgrades: Neutral
Price Target: n/a
Current: $27.54
Upside: -
Ascentage Pharma Group International
Nov 10, 2025
Initiates: Buy
Price Target: $50
Current: $32.00
Upside: +56.25%
TScan Therapeutics
Nov 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.99
Upside: -
Innate Pharma
Oct 29, 2025
Reiterates: Buy
Price Target: $8
Current: $1.80
Upside: +344.44%
Syndax Pharmaceuticals
Oct 27, 2025
Reiterates: Buy
Price Target: $56
Current: $17.09
Upside: +227.68%
IDEAYA Biosciences
Oct 21, 2025
Reiterates: Buy
Price Target: $62
Current: $33.71
Upside: +83.92%
Canaan
Oct 14, 2025
Reiterates: Buy
Price Target: $8
Current: $1.03
Upside: +676.70%
Viking Therapeutics
Sep 22, 2025
Reiterates: Buy
Price Target: $125
Current: $37.76
Upside: +231.04%
Jasper Therapeutics
Sep 22, 2025
Maintains: Buy
Price Target: $20 → $7
Current: $1.83
Upside: +282.51%
Verastem
Sep 9, 2025
Reiterates: Buy
Price Target: $20
Current: $9.27
Upside: +115.75%
Jan 10, 2025
Initiates: Buy
Price Target: $6
Current: $2.10
Upside: +185.71%
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $22.59
Upside: +85.92%
May 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.65
Upside: -
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $1.23
Upside: +64,940.65%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $38.06
Upside: +139.10%
Aug 10, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $0.60
Upside: +1,563.34%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $2.28
Upside: +601.75%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $29.42
Upside: +205.91%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $11.08
Upside: +179.78%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $47.55
Upside: -67.40%
Nov 16, 2022
Maintains: Buy
Price Target: $21 → $10
Current: $1.21
Upside: +726.45%